Omega-3 fats, sold as fish oil or algal oil supplements and as prescription medications, are used for heart, brain and healthy-aging goals. They reliably lower blood fats. A purified high-dose form reduced heart events in people on cholesterol-lowering drugs, but other trials did not, so heart protection remains contested. Low-dose use appears well tolerated with limited proven gains; higher doses bring a heart rhythm risk that rises with dose. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Omega-3 Index | ≥8% | Confirms adequate dosing |
| Triglycerides | <150 mg/dL | Main lipid effect |
| LDL cholesterol | <100 mg/dL | Safety check; DHA products can raise it |
| Blood pressure | <120/80 mm Hg | Expected to change modestly at 2–3 g/day |
| Heart rhythm (pulse or ECG) | No established target; track new irregularity versus baseline | Safety check for atrial fibrillation |
| INR (warfarin users) | 2.0–3.0 | Safety check for bleeding |
Cadence: Omega-3 Index and lipid panel at about 3–4 months, then every 6–12 months once stable; INR 1–2 weeks after starting alongside warfarin; blood pressure monthly during dose increases